{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T16:11:48Z","timestamp":1787069508035,"version":"build-2736575974"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2015,5,19]],"date-time":"2015-05-19T00:00:00Z","timestamp":1431993600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2015,5,19]],"date-time":"2015-05-19T00:00:00Z","timestamp":1431993600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Convenient drug-resistance testing of viral mutants is indispensable to effective treatment of viral infection. We developed a novel fluorometric assay for phenotypic differentiation of drug-resistant mutants of human immunodeficiency virus-I protease (HIV-PR) which uses enzymatic and peptide-specific fluorescence (FL) reactions and high-performance liquid chromatography (HPLC) of three HIV-PR substrates. This assay protocol enables use of non-purified enzyme sources and multiple substrates for the enzymatic reaction. In this study, susceptibility of HIV mutations to drugs was evaluated by selective formation of three FL products after the enzymatic HIV-PR reaction. This proof-of-concept study indicates that the present HPLC-FL method could be an alternative to current phenotypic assays for the evaluation of HIV drug resistance.<\/jats:p>","DOI":"10.1038\/srep10323","type":"journal-article","created":{"date-parts":[[2015,5,19]],"date-time":"2015-05-19T12:40:39Z","timestamp":1432039239000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Fluorometric assay for phenotypic differentiation of drug-resistant HIV mutants"],"prefix":"10.1038","volume":"5","author":[{"given":"Qinchang","family":"Zhu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiqiang","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tsutomu","family":"Kabashima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sheng","family":"Yin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shpend","family":"Dragusha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed F. M.","family":"El-Mahdy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valon","family":"Ejupi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takayuki","family":"Shibata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masaaki","family":"Kai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2015,5,19]]},"reference":[{"key":"BFsrep10323_CR1","doi-asserted-by":"crossref","first-page":"1805","DOI":"10.2174\/1381612053764869","volume":"11","author":"G Barbaro","year":"2005","unstructured":"Barbaro, G., Scozzafava, A., Mastrolorenzo, A. & Supuran, C. T. Highly active antiretroviral therapy: current state of the art, new agents and their pharmacological interactions useful for improving therapeutic outcome. Curr. Pharm. Des. 11, 1805\u20131843 (2005).","journal-title":"Curr. Pharm. Des."},{"key":"BFsrep10323_CR2","doi-asserted-by":"crossref","first-page":"e1001044","DOI":"10.1371\/journal.pmed.1001044","volume":"8","author":"A Edmonds","year":"2011","unstructured":"Edmonds, A. et al. The effect of highly active antiretroviral therapy on the survival of HIV-infected children in a resource-deprived setting: a cohort study. PLOS Med. 8, e1001044 (2011).","journal-title":"PLOS Med."},{"key":"BFsrep10323_CR3","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1093\/cid\/cis438","volume":"55","author":"J Luebbert","year":"2012","unstructured":"Luebbert, J. et al. Virological failure and drug resistance in patients on antiretroviral therapy after treatment interruption in Lilongwe, Malawi. Clin. Infect. Dis. 55, 441\u2013448 (2012).","journal-title":"Clin. Infect. Dis."},{"key":"BFsrep10323_CR4","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1001\/jama.2011.375","volume":"305","author":"JZ Li","year":"2011","unstructured":"Li, J. Z. et al. Low-frequency HIV-1 drug resistance mutations and risk of NNRTI-based antiretroviral treatment failure: a systematic review and pooled analysis. JAMA 305, 1327\u20131335 (2011).","journal-title":"JAMA"},{"key":"BFsrep10323_CR5","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1089\/aid.2011.0300","volume":"29","author":"K Kebe","year":"2013","unstructured":"Kebe, K. et al. High rate of antiretroviral drug resistance mutations in HIV type 1-infected Senegalese children in virological failure on first-line treatment according to the World Health Organization guidelines. AIDS Res. Hum. Retroviruses 29, 242\u2013249 (2013).","journal-title":"AIDS Res. Hum. Retroviruses"},{"key":"BFsrep10323_CR6","doi-asserted-by":"crossref","first-page":"S130","DOI":"10.1086\/651484","volume":"50","author":"LM Mofenson","year":"2010","unstructured":"Mofenson, L. M. Prevention in neglected subpopulations: prevention of mother-to-child transmission of HIV infection. Clin. Infect. Dis. 50 Suppl 3 S130\u2013148 (2010).","journal-title":"Clin. Infect. Dis."},{"key":"BFsrep10323_CR7","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1086\/375597","volume":"37","author":"MS Hirsch","year":"2003","unstructured":"Hirsch, M. S. et al. Antiretroviral drug resistance testing in adults infected with human immunodeficiency virus type 1: 2003 recommendations of an International AIDS Society-USA Panel. Clin. Infect. Dis. 37, 113\u2013128 (2003).","journal-title":"Clin. Infect. Dis."},{"key":"BFsrep10323_CR8","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1093\/cid\/cit665","volume":"58","author":"JA Aberg","year":"2014","unstructured":"Aberg, J. A. et al. Primary care guidelines for the management of persons infected with HIV: 2013 update by the HIV medicine association of the Infectious Diseases Society of America. Clin. Infect. Dis. 58, e1\u201334 (2014).","journal-title":"Clin. Infect. Dis."},{"key":"BFsrep10323_CR9","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1038\/35073673","volume":"410","author":"DD Richman","year":"2001","unstructured":"Richman, D. D. HIV chemotherapy. Nature 410, 995\u20131001 (2001).","journal-title":"Nature"},{"key":"BFsrep10323_CR10","doi-asserted-by":"crossref","first-page":"29621","DOI":"10.1074\/jbc.270.50.29621","volume":"270","author":"T Ridky","year":"1995","unstructured":"Ridky, T. & Leis, J. Development of drug resistance to HIV-1 protease inhibitors. J. Biol. Chem. 270, 29621\u201329623 (1995).","journal-title":"J. Biol. Chem."},{"key":"BFsrep10323_CR11","first-page":"67","volume":"10","author":"RW Shafer","year":"2008","unstructured":"Shafer, R. W. & Schapiro, J. M. HIV-1 drug resistance mutations: an updated framework for the second decade of HAART. AIDS Rev. 10, 67\u201384 (2008).","journal-title":"AIDS Rev."},{"key":"BFsrep10323_CR12","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1128\/AAC.41.3.515","volume":"41","author":"ML Smidt","year":"1997","unstructured":"Smidt, M. L. et al. A mutation in human immunodeficiency virus type 1 protease at position 88, located outside the active site, confers resistance to the hydroxyethylurea inhibitor SC-55389A. Antimicrob. Agents Chemother. 41, 515\u2013522 (1997).","journal-title":"Antimicrob. Agents Chemother."},{"key":"BFsrep10323_CR13","doi-asserted-by":"crossref","first-page":"29162","DOI":"10.1074\/jbc.270.49.29162","volume":"270","author":"L Menendez-Arias","year":"1995","unstructured":"Menendez-Arias, L., Weber, I. T. & Oroszlan, S. Mutational analysis of the substrate binding pocket of murine leukemia virus protease and comparison with human immunodeficiency virus proteases. J. Biol. Chem. 270, 29162\u201329168 (1995).","journal-title":"J. Biol. Chem."},{"key":"BFsrep10323_CR14","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1128\/JVI.76.3.1359-1368.2002","volume":"76","author":"DS Dauber","year":"2002","unstructured":"Dauber, D. S. et al. Altered substrate specificity of drug-resistant human immunodeficiency virus type 1 protease. J. Virol. 76, 1359\u20131368 (2002).","journal-title":"J. Virol."},{"key":"BFsrep10323_CR15","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/j.virol.2005.11.049","volume":"347","author":"M Kolli","year":"2006","unstructured":"Kolli, M., Lastere, S. & Schiffer, C. A. Co-evolution of nelfinavir-resistant HIV-1 protease and the p1-p6 substrate. Virology 347, 405\u2013409 (2006).","journal-title":"Virology"},{"key":"BFsrep10323_CR16","doi-asserted-by":"crossref","first-page":"3300","DOI":"10.1128\/JVI.72.4.3300-3306.1998","volume":"72","author":"V Zennou","year":"1998","unstructured":"Zennou, V., Mammano, F., Paulous, S., Mathez, D. & Clavel, F. Loss of viral fitness associated with multiple Gag and Gag-Pol processing defects in human immunodeficiency virus type 1 variants selected for resistance to protease inhibitors in vivo. J. Virol. 72, 3300\u20133306 (1998).","journal-title":"J. Virol."},{"key":"BFsrep10323_CR17","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.jcv.2004.07.008","volume":"32","author":"EC Bile","year":"2005","unstructured":"Bile, E. C. et al. Performance of drug-resistance genotypic assays among HIV-1 infected patients with predominantly CRF02_AG strains of HIV-1 in Abidjan, Cote d\u2019Ivoire. J. Clin. Virol. 32, 60\u201366 (2005).","journal-title":"J. Clin. Virol."},{"key":"BFsrep10323_CR18","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1016\/S0140-6736(05)62092-2","volume":"349","author":"SG Deeks","year":"1997","unstructured":"Deeks, S. G. & Abrams, D. I. Genotypic-resistance assays and antiretroviral therapy. Lancet 349, 1489\u20131490 (1997).","journal-title":"Lancet"},{"key":"BFsrep10323_CR19","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1128\/JCM.40.2.335-340.2002","volume":"40","author":"L Sarmati","year":"2002","unstructured":"Sarmati, L. et al. Discordance between genotypic and phenotypic drug resistance profiles in human immunodeficiency virus type 1 strains isolated from peripheral blood mononuclear cells. J. Clin. Microbiol. 40, 335\u2013340 (2002).","journal-title":"J. Clin. Microbiol."},{"key":"BFsrep10323_CR20","doi-asserted-by":"crossref","first-page":"8271","DOI":"10.1073\/pnas.112177799","volume":"99","author":"N Beerenwinkel","year":"2002","unstructured":"Beerenwinkel, N. et al. Diversity and complexity of HIV-1 drug resistance: a bioinformatics approach to predicting phenotype from genotype. Proc. Natl. Acad. Sci. USA 99, 8271\u20138276 (2002).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"BFsrep10323_CR21","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1093\/jac\/dkh157","volume":"53","author":"DD Richman","year":"2004","unstructured":"Richman, D. D. Benefits and limitations of testing for resistance to HIV drugs. J. Antimicrob. Chemother. 53, 555\u2013557 (2004).","journal-title":"J. Antimicrob. Chemother."},{"key":"BFsrep10323_CR22","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1007\/s11908-999-0032-4","volume":"1","author":"GJ Hanna","year":"1999","unstructured":"Hanna, G. J. & D\u2019Aquila, R. T. Antiretroviral Drug Resistance in HIV-1. Curr. Infect. Dis. Rep. 1, 289\u2013297 (1999).","journal-title":"Curr. Infect. Dis. Rep."},{"key":"BFsrep10323_CR23","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1590\/S1413-86702004000400003","volume":"8","author":"F Bahia","year":"2004","unstructured":"Bahia, F. et al. Evaluation of the genotypic pattern of HIV-1 resistance in AIDS patients failing antiretroviral therapy. Braz. J. Infect. Dis. 8, 281\u2013289 (2004).","journal-title":"Braz. J. Infect. Dis."},{"key":"BFsrep10323_CR24","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1007\/PL00015023","volume":"18","author":"N Villalba","year":"1999","unstructured":"Villalba, N., Gomez-Cano, M., Holguin, A. & Soriano, V. Multiple drug resistance genotype causing failure of antiretroviral treatment in an HIV-infected patient heavily exposed to nucleoside analogues. Eur. J. Clin. Microbiol. Infect. Dis. 18, 372\u2013375 (1999).","journal-title":"Eur. J. Clin. Microbiol. Infect. Dis."},{"key":"BFsrep10323_CR25","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1097\/00002030-200108170-00003","volume":"15","author":"AL Dunne","year":"2001","unstructured":"Dunne, A. L. et al. Comparison of genotyping and phenotyping methods for determining susceptibility of HIV-1 to antiretroviral drugs. AIDS 15, 1471\u20131475 (2001).","journal-title":"AIDS"},{"key":"BFsrep10323_CR26","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.1002\/jobm.201300415","volume":"54","author":"J Yang","year":"2014","unstructured":"Yang, J., Geng, W., Zhang, M., Han, X. & Shang, H. Discordance between genotypic resistance and pseudovirus phenotypic resistance in AIDS patients after long-term antiretroviral therapy and virological failure. J. Basic. Microbiol. 54, 1120\u20131125 (2014).","journal-title":"J. Basic. Microbiol."},{"key":"BFsrep10323_CR27","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1128\/AAC.38.1.23","volume":"38","author":"P Kellam","year":"1994","unstructured":"Kellam, P. & Larder, B. A. Recombinant virus assay: a rapid, phenotypic assay for assessment of drug susceptibility of human immunodeficiency virus type 1 isolates. Antimicrob. Agents Chemother. 38, 23\u201330 (1994).","journal-title":"Antimicrob. Agents Chemother."},{"key":"BFsrep10323_CR28","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1128\/AAC.42.2.269","volume":"42","author":"K Hertogs","year":"1998","unstructured":"Hertogs, K. et al. A rapid method for simultaneous detection of phenotypic resistance to inhibitors of protease and reverse transcriptase in recombinant human immunodeficiency virus type 1 isolates from patients treated with antiretroviral drugs. Antimicrob. Agents Chemother. 42, 269\u2013276 (1998).","journal-title":"Antimicrob. Agents Chemother."},{"key":"BFsrep10323_CR29","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1128\/AAC.44.4.920-928.2000","volume":"44","author":"CJ Petropoulos","year":"2000","unstructured":"Petropoulos, C. J. et al. A novel phenotypic drug susceptibility assay for human immunodeficiency virus type 1. Antimicrob. Agents Chemother. 44, 920\u2013928 (2000).","journal-title":"Antimicrob. Agents Chemother."},{"key":"BFsrep10323_CR30","first-page":"187","volume":"52","author":"S Sen","year":"2006","unstructured":"Sen, S., Tripathy, S. P. & Paranjape, R. S. Antiretroviral drug resistance testing. J. Postgrad. Med. 52, 187\u2013193 (2006).","journal-title":"J. Postgrad. Med."},{"key":"BFsrep10323_CR31","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/S0003-2670(00)82448-4","volume":"182","author":"M Kai","year":"1986","unstructured":"Kai, M. & Ohkura, Y. Selective determination of N-terminal tyrosine containing peptides by a novel fluorescence reaction with borate, hydroxylamine and cobalt(II). Anal. Chim. Acta 182, 177\u2013183 (1986).","journal-title":"Anal. Chim. Acta"},{"key":"BFsrep10323_CR32","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/0003-2670(93)80253-H","volume":"280","author":"E Kojima","year":"1993","unstructured":"Kojima, E., Ohba, Y., Kai, M. & Ohkura, Y. Phenylglyoxal and glyoxal as fluorogenic reagents selective for N-terminal tryptophan-containing peptides. Anal. Chim. Acta 280, 157\u2013162 (1993).","journal-title":"Anal. Chim. Acta"},{"key":"BFsrep10323_CR33","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1016\/j.peptides.2007.11.014","volume":"29","author":"T Kabashima","year":"2008","unstructured":"Kabashima, T. et al. A selective fluorescence reaction for peptides and chromatographic analysis. Peptides 29, 356\u2013363 (2008).","journal-title":"Peptides"},{"key":"BFsrep10323_CR34","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.ab.2012.10.018","volume":"433","author":"MS Rahman","year":"2013","unstructured":"Rahman, M. S., Kabashima, T., Yasmin, H., Shibata, T. & Kai, M. A novel fluorescence reaction for N-terminal Ser-containing peptides and its application to assay caspase activity. Anal. Biochem. 433, 79\u201385 (2013).","journal-title":"Anal. Biochem."},{"key":"BFsrep10323_CR35","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/j.aca.2012.01.035","volume":"721","author":"H Yasmin","year":"2012","unstructured":"Yasmin, H., Shibata, T., Rahman, M. S., Kabashima, T. & Kai, M. Selective and sensitive determination of peptides using 3,4-dihydroxyphenylacetic acid as a fluorogenic reagent. Anal. Chim. Acta 721, 162\u2013166 (2012).","journal-title":"Anal. Chim. Acta"},{"key":"BFsrep10323_CR36","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1007\/s10989-014-9406-z","volume":"20","author":"H Yasmin","year":"2014","unstructured":"Yasmin, H., Rahman, M., Shibata, T., Kabashima, T. & Kai, M. A Novel Fluorometric Method for the Selective Determination of Pro-Gly and Pro-Gly-Pro. Int. J. Pept. Res. Ther. 20, 441\u2013446 (2014).","journal-title":"Int. J. Pept. Res. Ther."},{"key":"BFsrep10323_CR37","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1248\/cpb.39.126","volume":"39","author":"GQ Zhang","year":"1991","unstructured":"Zhang, G. Q., Kai, M., Nakano, M. & Ohkura, Y. Pre-column fluorescence derivatization high-performance liquid chromatography of opioid peptides in rat brain and its use for enzymatic peptide characterization. Chem. Pharm. Bull (Tokyo) 39, 126\u2013129 (1991).","journal-title":"Chem. Pharm. Bull (Tokyo)"},{"key":"BFsrep10323_CR38","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/0021-9673(93)83179-V","volume":"653","author":"M Kai","year":"1993","unstructured":"Kai, M., Kojima, E., Ohkura, Y. & Iwasaki, M. High-performance liquid chromatography of N-terminal tryptophan-containing peptides with precolumn fluorescence derivatization with glyoxal. J. Chromatogr. A 653, 235\u2013240 (1993).","journal-title":"J. Chromatogr. A"},{"key":"BFsrep10323_CR39","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.ab.2009.10.030","volume":"397","author":"Z Yu","year":"2010","unstructured":"Yu, Z. et al. Selective and facile assay of human immunodeficiency virus protease activity by a novel fluorogenic reaction. Anal. Biochem. 397, 197\u2013201 (2010).","journal-title":"Anal. Biochem."},{"key":"BFsrep10323_CR40","doi-asserted-by":"crossref","first-page":"4950","DOI":"10.1038\/srep04950","volume":"4","author":"H Yasmin","year":"2014","unstructured":"Yasmin, H., Kabashima, T., Rahman, M. S., Shibata, T. & Kai, M. Amplified and selective assay of collagens by enzymatic and fluorescent reactions. Sci. Rep. 4, 4950 (2014).","journal-title":"Sci. Rep."},{"key":"BFsrep10323_CR41","first-page":"1","volume":"2001","author":"RW Shafer","year":"2001","unstructured":"Shafer, R. W., Dupnik, K., Winters, M. A. & Eshleman, S. H. A Guide to HIV-1 Reverse Transcriptase and Protease Sequencing for Drug Resistance Studies. HIV Seq. Compend. 2001, 1\u201351 (2001).","journal-title":"HIV Seq. Compend."},{"key":"BFsrep10323_CR42","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/S0166-0934(03)00065-X","volume":"109","author":"H Gehringer","year":"2003","unstructured":"Gehringer, H. et al. Development and evaluation of a phenotypic assay monitoring resistance formation to protease inhibitors in HIV-1-infected patients. J. Virol. Methods 109, 143\u2013152 (2003).","journal-title":"J. Virol. Methods"},{"key":"BFsrep10323_CR43","doi-asserted-by":"crossref","first-page":"17979","DOI":"10.1074\/jbc.271.30.17979","volume":"271","author":"S Pazhanisamy","year":"1996","unstructured":"Pazhanisamy, S. et al. Kinetic characterization of human immunodeficiency virus type-1 protease-resistant variants. J. Biol. Chem. 271, 17979\u201317985 (1996).","journal-title":"J. Biol. Chem."},{"key":"BFsrep10323_CR44","doi-asserted-by":"crossref","first-page":"9458","DOI":"10.1128\/JVI.75.19.9458-9469.2001","volume":"75","author":"ZQ Beck","year":"2001","unstructured":"Beck, Z. Q., Lin, Y. C. & Elder, J. H. Molecular basis for the relative substrate specificity of human immunodeficiency virus type 1 and feline immunodeficiency virus proteases. J. Virol. 75, 9458\u20139469 (2001).","journal-title":"J. Virol."},{"key":"BFsrep10323_CR45","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1128\/JVI.75.2.589-594.2001","volume":"75","author":"HC Cote","year":"2001","unstructured":"Cote, H. C., Brumme, Z. L. & Harrigan, P. R. Human immunodeficiency virus type 1 protease cleavage site mutations associated with protease inhibitor cross-resistance selected by indinavir, ritonavir, and\/or saquinavir. J. Virol. 75, 589\u2013594 (2001).","journal-title":"J. Virol."},{"key":"BFsrep10323_CR46","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/S0042-6822(95)80069-7","volume":"206","author":"H Jacobsen","year":"1995","unstructured":"Jacobsen, H. et al. Characterization of human immunodeficiency virus type 1 mutants with decreased sensitivity to proteinase inhibitor Ro 31-8959. Virology 206, 527\u2013534 (1995).","journal-title":"Virology"},{"key":"BFsrep10323_CR47","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1529\/biophysj.104.046110","volume":"88","author":"K Wittayanarakul","year":"2005","unstructured":"Wittayanarakul, K. et al. Insights into saquinavir resistance in the G48V HIV-1 protease: quantum calculations and molecular dynamic simulations. Biophys. J. 88, 867\u2013879 (2005).","journal-title":"Biophys. J."},{"key":"BFsrep10323_CR48","first-page":"156","volume":"19","author":"VA Johnson","year":"2011","unstructured":"Johnson, V. A. et al. 2011 update of the drug resistance mutations in HIV-1. Top Antivir. Med. 19, 156\u2013164 (2011).","journal-title":"Top Antivir. Med."},{"key":"BFsrep10323_CR49","doi-asserted-by":"crossref","first-page":"4253","DOI":"10.1128\/AAC.00574-10","volume":"54","author":"SY Rhee","year":"2010","unstructured":"Rhee, S. Y. et al. HIV-1 protease mutations and protease inhibitor cross-resistance. Antimicrob. Agents Chemother. 54, 4253\u20134261 (2010).","journal-title":"Antimicrob. Agents Chemother."},{"key":"BFsrep10323_CR50","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1093\/molbev\/msj098","volume":"23","author":"TL O\u2019Loughlin","year":"2006","unstructured":"O\u2019Loughlin, T. L., Greene, D. N. & Matsumura, I. Diversification and specialization of HIV protease function during in vitro evolution. Mol. Biol. Evol. 23, 764\u2013772 (2006).","journal-title":"Mol. Biol. Evol."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/srep10323","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/srep10323.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/srep10323.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,5]],"date-time":"2023-01-05T09:10:08Z","timestamp":1672909808000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/srep10323"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,5,19]]},"references-count":50,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2015,9,22]]}},"alternative-id":["BFsrep10323"],"URL":"https:\/\/doi.org\/10.1038\/srep10323","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,5,19]]},"assertion":[{"value":"22 December 2014","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 April 2015","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 May 2015","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing financial interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"10323"}}